Skip to main content

Ocimum Gets Up to $17M Capital Investment, Closes Gene Logic Genomics Biz Buy

NEW YORK (GenomeWeb News) – Ocimum Biosolutions has landed an equity investment of up to $17 million and has closed its acquisition of Gene Logic’s genomics division, the company said today.
 
The capital investment came from Kubera Cross Border Fund, as well as affiliates of Kubera Partners, which manages KUBC.
 
Ocimum said that the acquired genomics business will retain the Gene Logic name and will continue operating out of Gaithersburg, Md.
 
Ocimum agreed in October to pay $10 million for the Gene Logic genomics division, including $7 million up front and $3 million in 18 months.
 
Including the newly acquired Maryland office, Ocimum now has operations in Indianapolis, the Netherlands, and India, the firm said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.